

2 **Supporting Information for**

3 *Trichomonas vaginalis* extracellular vesicles upregulate and directly
4 transfer adherence factors promoting host cell colonization

5
6 Joshua A. Kochanowsky^a, Portia Mira^a, Samira Elikae^a, Katherine Muratore^a, Anand Kumar
7 Rai^a, Angelica M. Riestra^{a, b}, and Patricia J. Johnson^a

8 ^aDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los
9 Angeles, CA 90095

10 ^bDepartment of Biology, San Diego State University, San Diego, CA 92182

11 *Patricia J. Johnson.

12 **Email:** johnsonp@ucla.edu

13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **This PDF file includes:**

28 Supplemental Methods

29 Figures S1 to S8

30 Tables S1-2

31 Legends for Movies S1

32 Legends for Datasets S1 to S11

33

34 **Other supporting materials for this manuscript include the following:**

35

36 Movies S1

37 Datasets S1 to S11

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55 **Supplemental Methods**

56

57 **Generation of transgenic parasites.** Nucleofection of *T. vaginalis* strain G3 with 15 µgs of the
58 resulting vectors or an empty vector control was done as described previously (52). Transfectants
59 were selected and maintained using 100 µgs/ml G418. CLP and CLP-MUT transgenic parasites
60 were generated using vectors previously described (52). The constructs were transfected into *T.*
61 *vaginalis* strain G3, and parasites containing the constructs were selected using 100 µgs/ml G418.
62 All primers used for cloning are listed in (*SI Appendix*, Table S1).

63

64 **PCR verification of CLP and CLP-MUT transgenic parasites.** To confirm the presence of the
65 CLP and CLP-MUT gene in our transgenic parasites, total genomic DNA was isolated and then
66 used in a PCR reaction with primers pMN_Out_REV-gactccactcaagacgtcac and
67 pMN_aSCS_FWD-aacaggagaaacgattgcccc.

68

69 **Immunofluorescent verification of CLP, HPB2, and HPB3 overexpressing parasites.** For
70 immunofluorescence assays, CFSE-labeled *Trichomonas* were fixed with 4% paraformaldehyde
71 for 15 minutes. The parasites were then permeabilized and blocked for 60 minutes with 0.1–0.2%
72 (vol/vol) Triton-X 100 in PBS (pH 7.4), with 3% (wt/vol) goat serum. Cells were then incubated with
73 rabbit anti-HA (1:500) (Cell Signaling Technologies; Cat. #3724S) overnight at 4°C, followed by
74 incubation with anti-rabbit CF583R at 1:500 (Biotium; Cat. #20793-50µL) and Hoechst (Biotium;
75 Cat. #40044) for 1 hour at room temperature.

76

77 **Western blot verification of CLP and CLP-MUT transgenic parasites.** Mouse anti-GFP
78 polyclonal antibody (1:1,000; Clontech) and anti-TVGAPDH (1:10,000; Cocalico Biologicals) were
79 used as the primary antibodies, and horseradish peroxidase (HRP)-conjugated anti-mouse
80 (1:25,000) and anti-rabbit (1:25,000) antibodies (Jackson Laboratory) were used as the secondary
81 antibodies. A total of 1×10^6 parasites were taken from *T. vaginalis* cultures and washed with 1x
82 PBS plus 5% sucrose plus 1x Halt protease inhibitor cocktail (Thermo Fisher Scientific). The cells

83 were then lysed in RIPA buffer (Thermo Fischer Scientific) plus 1x Halt protease inhibitor cocktail
84 (Thermo Fisher Scientific). The protein concentration was quantified using Pierce BCA Kit (Thermo
85 Scientific #23225) and equal amounts of protein were loaded from each sample.

86

87 **Extracellular vesicle uptake assay.** Parasites were spun and resuspended in Dulbecco's Gibco
88 Phosphate Buffered Saline (DPBS #14190-144) at 1×10^6 cells/mL. CFSE-labeled TvEVs were
89 added to parasites, incubated at 37°C for the indicated timepoints and fixed in 100 μ Ls 4% PFA for
90 15 minutes at room temperature, then resuspended in 1 mL 1x DBPS for FACS analysis or imaging
91 on Operetta® CLS™ platform (48). FACS analysis was performed using the LSRII Analyzer. Cells
92 were first gated to include all cells and discard cellular debris. The second gate included only single
93 cells and discarded all doublets. The third gate quantified the percent CFSE positive cells based
94 on the unlabeled negative control. Percent uptake was then calculated by dividing the number of
95 CFSE positive parasites by the number of total parasites multiplied by 100. MFI for CFSE is
96 calculated from the total population of parasites (P2 gate). To measure TvEV uptake using the
97 Operetta® CLS™ platform, we additionally stained the fixed cells with ZombieRed (Biolegend)
98 (1:1000) for 30 minutes at room temperature, washed and resuspended in 1x PBS. Cells were then
99 plated onto a 96-well black, clear bottom plate and imaged. Images were analyzed using
100 Harmony™ software. Total parasites were identified and enumerated via ZombieRed staining using
101 the standard nuclei identification module. CFSE positive parasites were identified using the
102 Harmony™ identify population tool. Fluorescent intensity cutoffs were set at 1,000 and length and
103 width cutoffs were set at 5 μ m and 2 μ m respectively to filter out small auto-fluorescent debris.
104 Percent uptake was then calculated by dividing the number of CFSE positive parasites by the
105 number of total parasites multiplied by 100. MFI for CFSE is calculated from the total population of
106 parasites identified using zombieRED.

107

108 **Adherence assay.** 1×10^6 CFSE-labeled *T. vaginalis* parasites were incubated with the indicated
109 amount of TvEVs for 30 minutes and then 5×10^4 parasites were added to confluent monolayers
110 of BPH-1s for 1 hour. Unattached parasites were washed off and cells were fixed in 4%

111 formaldehyde in 1x PBS for 20 minutes at room temperature. Plates were imaged using the
112 Operetta® CLS™ platform, high throughput microplate imaging system and analyzed using
113 Harmony™ software. CFSE positive parasites were identified using the Harmony™ identify cells
114 tool. Fluorescent intensity cutoffs were set at 1,000 and length and width cutoffs were set at 5 µms
115 and 2 µms respectively to filter out small auto-fluorescent debris. The % attachment was
116 determined as the number of parasites in the well divided by input (5×10^4) multiplied by 100.

117

118 **Aggregation assay.** G3 parasites (1×10^6 cells/mL) were spun down at 3200 rpm for 10 minutes.
119 Pellets were resuspended in 1 mL 1x DPBS. Parasites were labeled with CFSE (1:1000) and
120 TvEVs were added at 20 µgs/mL or BSA as a control. Parasites were vortexed briefly and
121 transferred to a black, clear-bottom 96-well plate (100 µLs/well) in triplicate. Plates were incubated
122 at 37°C for 30 minutes. Afterwards, 100 µLs of 8% PFA was added (final 4% PFA concentration)
123 to fix the cells and incubated at room temperature for 15 minutes. Plates were spun at 300 rpm for
124 5 minutes before removing PFA and adding 100 µLs of 1x DPBS for imaging. Plates were imaged
125 using the Operetta® CLS™ platform, high throughput microplate imaging system and analyzed
126 using Harmony™ software. CFSE-positive parasites were identified using the Harmony™ identify
127 cell tool. Fluorescent intensity cutoffs were set at 1,000 and length and width cutoffs were set at 5
128 µms and 2 µms respectively to filter out small auto-fluorescent debris. Parasites 'clumps' were
129 counted as an aggregate if they exceeded 250 µms in diameter. |

130

131 **Immunofluorescence for dSTORM.** dSTORM imaging of parasite incubated with TvEVs was
132 performed as follows. *T. vaginalis* strain G3 was incubated with 50 µgs/mL of CLP-EVs or WT-EVs,
133 as a negative control, for 30 minutes. Parasites were then fixed and stained using dSTORM
134 Discovery Kit with Strong Fixative (Onibio) using fixative b protocol. Briefly, parasites were fixed
135 with 4% PFA-0.2% glutaraldehyde for 10 minutes followed by quenching with Discovery Kit
136 quenching solution for 7 minutes. Parasites were then blocked with 5% BSA in 1x PBS for 1 hour
137 at room temperature. Parasites were not permeabilized to ensure any CLP signal originated from
138 the surface of the parasite rather than reflecting CLP that had been internalized. Parasites were

139 then incubated in Mouse anti-GFP polyclonal antibody (1:1,000; Clontech) overnight at 4°C,
140 followed by incubation with goat anti-mouse Alexa Fluor 647 (1:500; Invitrogen Cat. # A-21235) for
141 1 hour at room temperature. Parasites were then imaged on a Nanoimager (Onibio) at 100x
142 magnification.

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162


163

164

165

166

167 Supplemental Figures



168

169 **Figure S1.** Validation of TvEV isolation method. (A) Bicinchoninic acid (BCA) assay standard curve
 170 using bovine serum albumin as a standard for calculating protein concentration of isolated TvEVs.
 171 (B) Absorbance values for either a mock (Diamond's media alone) or TvEV preparation. (C)
 172 Calculated concentration of either mock (Diamond's media alone) or TvEV preparation in milligrams
 173 per milliliters using equation generated in (A) multiplied by 6 to account for dilution factor. (D and
 174 E) Mean Fluorescent Intensity (MFI) and Percent uptake of *T. vaginalis* strain G3 fed either a mock
 175 preparation or TvEVs for 30mins. For mock treated parasites equivalent volumes of mock

176 preparation were used as the amount of protein was below the detectable limit for BCA analysis.

177 Dots = mean \pm SD. N = 3 wells/experiment, 3 experiments total.

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198


199

200

201

202

203



204

205 **Figure S2.** Example of gating scheme for Figure 1. (A) P1 – Parasites were first gated on forward
 206 and side scatter. (B) P2 – Doublets were excluded so that single parasites were counted. (C) P3 –
 207 TvEV fed parasites were then identified by CFSE positivity (labeled FITC-A on Y-axis). P3 events
 208 (CFSE positive parasites) were used to calculate % positive of population divided by the total
 209 number of parasite events recorded (Gate P2). MFI values were calculated from the entire P2
 210 population.

211

212

213


214

215

216

217

218



219

220 **Figure S3.** B7RC2-EVs are taken up more efficiently than G3-EVs. (A, B) Quantification of %
 221 uptake and total MFI between G3-EVs and B7RC2-EVs at (A) 2.5 µg/mL and (B) 10 µg/mL. Bars,
 222 mean ± SD. N = 3 wells/experiment, 3 experiments total. Numbers above bars indicate p-values
 223 for two-way ANOVA, Dunnett's multiple comparisons test compared to G3-EVs.

224

225

226

227


228

229

230

231

232



233

234 **Figure S4.** MultiQC summary of RNA-seq data. (A and B) Summary of number of reads and
 235 percentage of reads for each sample that pseudoaligned to the *T. vaginalis* G3 transcriptome
 236 available on TrichDB (<https://trichdb.org/common/downloads/release-64/TvaginalisG32022/fasta/data/>). (C and B) Per sequence Phred score and adapter content for
 237 each sample summarized using MultiQC.
 238

239

240

241

242

243


244

245

246

247

248



249

250 **Figure S5.** GO enrichment summary of down-regulated DEGs from RNA-seq data. Number of *T.*
 251 *vaginalis* genes in each significantly enriched GO annotation for molecular function (MF), biological
 252 process (BP), and cellular compartment (CC). Full set of GO annotations can be found in Dataset
 253 S3-5.

254

255

256

257

258


259

260


261

262


A.



B.



C.



263

264 **Figure S6.** Overexpression of CLP, HPB2, and HPB3 in *T. vaginalis* strain G3. (A) Representative
265 IFA of HA-tag on CLP, HPB2, and HPB3. Images depict Hoechst (Blue), CFSE-labelled *T. vaginalis*
266 strain G3 (Green) and CF583R conjugated secondaries for the HA-tag on each of the above
267 indicated proteins (Red). Quantification of % of parasites positive for CF583R signal. (C) MFI of
268 parasites stained for HA-tag on each of the above indicated proteins. (B and C) Bars, mean \pm SD.
269 N = 3 wells/experiment, 3 experiments total. Numbers above bars indicate p-values for one-way
270 ANOVA, Dunnett's multiple comparisons test compared to G3::EV.

271

272


273

274

275

276

277



278

279 **Figure S7.** PCR confirmation of CLP and CLP-MUT G3 strains. (A) Expected size = 2970bp. (B)
 280 *Top*, Western blot analysis of CLP overexpression in *T. vaginalis* strain G3. *Bottom*, Western blot
 281 analysis of CLP overexpression in TvEVs derived from indicated strains. GAPDH is used as host cell
 282 protein loading control and MIF is used as a TvEV resident protein control.

283

284

285

286

287

288


289

290

291

292

293



295

296 **Figure S8.** RT-PCR screen for *Trichomonas vaginalis* virus (TVV1-4) in *T. vaginalis* strain B7RC2.297 (A) RT-PCR screen for TVV1, or 4 in *T. vaginalis* strains NYH209 (positive control containing

298 TVV1), LSU160 (positive control containing both TVV1 & 4) and B7RC2. Expected size for TVV1

299 = 652bp. Expected size for TVV4 = 700bp. (B) RT-PCR screen for TVV2 and TVV3 in *T. vaginalis*

300 strains LSU160 (positive control containing both TVV2 & 3) and B7RC2. Expected size for TVV2

301 and TVV3 = 680bp. Positive signals for TVV1-4 are observed in the reverse transcriptase (RT)+

302 samples for positive control strains. No signal is observed for TVV1-4 in B7RC2.

303

304

305

306

307

Table S1. List of Top 10 most significantly up-regulated DEGs.

Gene ID (2022 Reference)	Gene ID (2013 Reference)	Product Description	log2(FC)	padj
TVAGG3_0964910	TVAG_097730	Secreted RxLR effector peptide	1.53946691	4.06E-09
TVAGG3_0232100	TVAG_157940	heteropolysaccharide binding	1.15253797	4.19E-09
TVAGG3_0392810	TVAG_185520	bacterial hemolysins family	1.36428372	4.19E-09
TVAGG3_0969590	TVAG_222040	heteropolysaccharide binding	1.71079909	4.19E-09
TVAGG3_0163930	TVAG_154680	heteropolysaccharide binding	1.28699709	5.25E-09
TVAGG3_0430810	TVAG_239840	Major Facilitator Superfamily protein family	1.10461903	1.05E-08
TVAGG3_0606520	TVAG_237690	actin filament capping	1.03031125	1.26E-08
TVAGG3_0583720	TVAG_393390	unspecified product (cadherin-like protein)	0.89773958	1.39E-08
TVAGG3_0410780	TVAG_414870	unspecified product	1.1369581	1.58E-08

309

310

311

312

313

314

315

316

317

318

319

320

Table S2. Primers used throughout this study. Sequences listed 5'-3'		
Primer Name	Sequence	Use
pMN_Out_REV	GACTCCACTCAAGACGTAC	PCR verification in Figure S6
pMN_aSCS_FWD	AACAGGAGAAACGATTGCCCC	PCR verification in Figure S6
pMNeo_IF_FWD	TACCCATACGATGTTCCAGATTACG	In-fusion cloning for vector (pMNeo) backbone
pMNeo_IF_REV	ATGATGTGAAGTGAACAAAGCC	In-fusion cloning for vector (pMNeo) backbone
CLP_pMNeo_IF_FWD	TTCACTTCACATCATATGATTTGGACTTTTTTATTGCAGG	In-fusion cloning for CLP
CLP_pMNeo_IF_REV	AACATCGTATGGGTACTTTCTAAGCCAAAGAATTATTACT	In-fusion cloning for CLP
HPB2_pMNeo_IF_FWD	TTCACTTCACATCATATGATCTCAGCAACATCAGTAAATG	In-fusion cloning for HPB2
HPB2_pMNeo_IF_REV	AACATCGTATGGGTATATTCTGTGTGAATCGCGAAC	In-fusion cloning for HPB2
HPB3_pMNeo_IF_FWD	TTCACTTCACATCATATGATCTCCACATCAGCCAATGGA	In-fusion cloning for HPB3
HPB3_pMNeo_IF_REV	AACATCGTATGGGTATATTCTGTGGGAATCACGAACGAGT	In-fusion cloning for HPB3
TVV1_FWD	CACTTGACCGGATCTTGCCTCGCAT	RT-PCR screen for TVV1 Figure S8
TVV1_REV	TATTACGGGGCCACAACGTACAGCT	RT-PCR screen for TVV1 Figure S8
TVV2_FWD	TACTAATAGTGACTGCGGTCCCTGA	RT-PCR screen for TVV2 Figure S8
TVV2_REV	GATCCGTAGATTTGGCTCATCGCCA	RT-PCR screen for TVV2 Figure S8
TVV3_FWD	CTGACTCAGTCAGACCAGTCCAAC	RT-PCR screen for TVV3 Figure S8

TVV3_REV	CCTTGC GTTGGATGATGTCCATGTA	RT-PCR screen for TVV3 Figure S8
TVV4_FWD	ACCTGCC CAGTTTTCGATGGTTCACA	RT-PCR screen for TVV4 Figure S8
TVV4_REV	GTGAGGCTTTGCGGATGAGGCCT	RT-PCR screen for TVV4 Figure S8

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343 **Movie S1 (separate file).** Exoglow™ Green-labeled TvEVs are internalized by *T. vaginalis*. Time-
344 lapse video showing the uptake of fluorescently labeled G3-EVs by *T. vaginalis* strain G3.
345

346 **Dataset S1 (separate file).** Gene expression data for *T. vaginalis* treated with TvEVs compared to
347 mock.

348 **Dataset S2 (separate file).** Down-regulated DEGs for *T. vaginalis* treated with TvEVs compared
349 to mock.

350 **Dataset S3 (separate file).** Gene Ontology for Molecular Function of down-regulated DEGs.

351 **Dataset S4 (separate file).** Gene Ontology for Biological Process of down-regulated DEGs.

352 **Dataset S5 (separate file).** Gene Ontology for Cell Compartment of down-regulated DEGs.

353 **Dataset S6 (separate file).** Up-regulated DEGs for *T. vaginalis* treated with TvEVs compared to
354 mock.

355 **Dataset S7 (separate file).** Gene Ontology for Molecular Function of up-regulated DEGs.

356 **Dataset S8 (separate file).** Gene Ontology for Biological Process of up-regulated DEGs.

357 **Dataset S9 (separate file).** Gene Ontology for Cell Compartment of up-regulated DEGs.

358 **Dataset S10 (separate file).** Protein abundance data for B7RC2-EVs vs NYH209-EVs.

359 **Dataset S11 (separate file).** Differentially abundant proteins B7RC2-EVs vs NYH209-EVs.